Bettina Schmitz

Bettina Schmitz

Auto-generated profile, based on publicly available information

Bettina Schmitz

Stroke Unit, Clinic for Neurology, Epilepsy Center Vivantes‐Humboldt Clinic Berlin Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2026 in Epilepsia
Verified
Journal Article
Open access
PDF file
BTBarbara Tettenborn
Barbara Tettenborn
GRGeorgia Ramantani
Georgia Ramantani
DFDominique Flügel
Dominique Flügel
VGVerena Gaus
Verena Gaus
SSSusanne Schubert‐Bast
Susanne Schubert‐Bast
BSBettina Schmitz
Bettina Schmitz
Women with epilepsy (WWE) encounter distinct and evolving challenges across the lifespan that require clinical management extending beyond seizure control alone. Although awareness of sex‐specific aspects of epilepsy has increased, important gaps remain in their integration into routine care. This review synthesizes current evidence on epilepsy management across key life stages, including adolescence and transition to adult care, reproductive health, contraception, fertility and pregnancy, lactation, menopause, and bone health. It integrates recent literature with expert interpretation in alignment with contemporary clinical guidelines, with the aim of enhancing clinical applicability. Hormonal changes, bidirectional interactions between antiseizure medications (ASMs), and reproductive physiology as well as shifting psychosocial demands influence seizure patterns, treatment efficacy, and long‐term health outcomes in WWE. Particular focus is placed on interactions between epilepsy, endocrine regulation, and ASM therapy, and on teratogenic and neurodevelopmental risks associated with specific ASMs. Effective care for WWE requires continuous, individualized counseling that adapts to changing priorities and risks over time. Structured transition processes, evidence‐based counseling on contraception and pregnancy, therapeutic drug monitoring during pregnancy, and transparent communication regarding fetal risks of ASMs are essential components of high‐quality care. Beyond the reproductive years, seizure changes during menopause and the cumulative impact of long‐term ASM exposure, particularly on bone health, require surveillance and prevention. Despite advances in pregnancy registries and treatment recommendations, participation in registries is low, and evidence outside pregnancy remains limited. Awareness of sex‐specific epilepsy issues continues to be insufficient among both WWE and health care professionals. Addressing these gaps will require improved education, coordinated multidisciplinary care, and expanded research efforts to support patient‐centered, lifelong care for WWE.

18 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
JSJan Sobesky
Jan Sobesky
VMVince Istvan Madai
Vince Istvan Madai
SZSarah Zweynert
Sarah Zweynert
CMCarolin Malsch
Carolin Malsch
DNDarius Guenther Nabavi
Darius Guenther Nabavi
PHPeter Ulrich Heuschmann
Peter Ulrich Heuschmann
Background: Early stroke complications (ESCs) impair recovery and provide an important therapeutic target. Our multicenter prospective cohort study examined the prevalence and amount of poor outcomes attributable to ESCs. Methods and Results: In patients with stroke, 16 ESCs were monitored by clinical assessment (“basic definition”) and by inclusion of laboratory values and clinical scales (“extended definition”). The association of complications with poor outcome (death or functional impairment: modified Rankin Scale score >3 or Barthel Index <60) at 3 months was analyzed using multiple logistic regression adjusted for stroke severity, age, and sex. Complications were stratified by their early treatment options, and average sequential population‐attributable fractions were estimated for treatable early complications. Of 1202 patients, outcome data were available for 1105 (91.9%; 43.0% women; mean age 68.3 years; baseline median National Institutes of Health Stroke Scale score on admission 3 points). Poor outcome was recorded for 100 patients (9.0%). By basic definition, recurrent stroke, fever, pneumonia, depression, urinary tract infection, and delirium were significantly associated with poor outcomes. The occurrence of 1 or more of these ESCs was associated with up to 19.6% of poor outcomes. By extended definition, urinary tract infection, depression, and delirium were significantly associated with poor outcomes. The occurrence of 1 or more of these ESCs was associated with up to 15.9% of poor outcomes. Conclusions: In our cohort of patients with mild to moderate stroke, we identified a set of treatable ESCs with clinically relevant impact on outcome that may be targeted in future interventional trials. Registration: URL: https://www.bfarm.de ; Unique identifier: DRKS00004712.

27 March 2026 in Epilepsia Open
Verified
Journal Article
Open access
SLSimona Lattanzi
Simona Lattanzi
BSBettina Schmitz
Bettina Schmitz
NCNuno Canas
Nuno Canas
JLJohn Paul Leach
John Paul Leach
CBCaroline Benoist
Caroline Benoist
EÁElena Álvarez‐Barón
Elena Álvarez‐Barón
Objective: Drug‐resistant epilepsy (DRE) imposes a significant burden on patients and their caregivers. This study aimed to explore the concerns and perceptions of healthcare providers (HCPs), patients, and caregivers regarding the burden of disease and quality of life (QoL) in patients with DRE. Methods: This was a multinational, cross‐sectional, online, survey‐based study. Participants were HCPs managing at least 30–50 epilepsy patients per month, including ≥10 patients with DRE; patients aged ≥18 years with DRE; and caregivers aged ≥18 years supporting patients with DRE. Data collection was carried out between March and August 2024. Results: In total, 213 stakeholders took part in the survey (146 HCPs, 42 patients, and 25 caregivers); 58% of the HCPs were neurologists and 42% were epileptologists. Caregivers were mainly parents (79%). Patients represented by caregivers were younger (84% vs. 29% aged 18–34 years) and had a higher incidence of seizures (20 vs. 5 seizures per month; p < 0.05) than patient participants. According to all stakeholders, DRE had a significant impact on multiple components of patient QoL, with work capability, psychological well‐being, and daily management and logistics the most affected. Significantly fewer HCPs regarded “achieving complete seizure freedom” as of high importance for patients compared with patient participants ( p < 0.05) and caregivers ( p < 0.05). High satisfaction with current treatment was reported by only 35% of HCPs, 33% of patient participants, and 4% of caregivers. Most stakeholders reported insufficient time during consultations to investigate patients' concerns, and different topics for discussion were prioritized by HCPs and patients/caregivers. Significance: This survey highlighted the continued and multifaceted burden of disease among patients with DRE. While seizure freedom is the ultimate goal of treatment, disparities exist among key stakeholders regarding aims and outcomes of treatment as well as management of expectations. Plain Language Summary: Patients with DRE have epileptic seizures despite receiving medicines to reduce their seizures. This survey shows that DRE places a heavy strain on patients and their carers. Satisfaction with current treatments is low, especially among carers. Patients and carers see stopping all seizures as very important, but doctors tend to rate this as less of a priority; patients and carers are also more open than doctors to using digital tools to improve communication with their doctor. Overall, the differences in expectations and approaches between patients, carers, and doctors may create barriers to improving seizure control.